The authors have retracted this Correspondence article because, after publication, they became aware that it inadvertently contains some data from a manuscript in preparation that will report the outcome of this clinical trial in full. In addition, as this article contains potentially identifying information, the content is no longer available online in order to protect patient confidentiality. All authors agree to this retraction.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have retracted this Correspondence article because, after publication, they became aware that it inadvertently contains some data from a manuscript in preparation that will report the outcome of this clinical trial in full. In addition, as this article contains potentially identifying information, the content is no longer available online in order to protect patient confidentiality. All authors agree to this retraction.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Parrondo, R.D., Sam, K., Rasheed, A. et al. RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis. Blood Cancer J. 12, 66 (2022). https://doi.org/10.1038/s41408-022-00662-0
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41408-022-00662-0
